| Interacting proteins: P09619 and P04049 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P09619 and P04049 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P09619 and P04049 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P09619 and P04049 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P09619 and P04049 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P09619 and P04049 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P09619 and P04049 |
Pubmed |
SVM Score :0.0 |
| Under the same conditions , neither mobility shift of raf 1 nor tyrosine phosphorylation of either PLC gamma or MAP kinase was impaired . 32D transfectants expressing the double mutant showed wild type alpha PDGFR levels of mitogenic and chemotactic responses to PDGF . ^^^ |
|
| Interacting proteins: P09619 and P04049 |
Pubmed |
SVM Score :0.0 |
| Sorafenib is the first oral multi kinase inhibitor to be developed that targets Raf kinases ( Raf 1 , wild type B Raf , and b raf V600E ) , in addition to receptor tyrosine kinases associated with angiogenesis ( vascular endothelial growth factor receptor [ VEGFR ] 2 / 3 , platelet derived growth factor receptor [ PDGFR ] beta ) or tumor progression ( Flt 3 , c kit ) . ^^^ |
|